Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | TACR2 | P21452 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509992 | 0.94 | ALDH1A1 (0.52) | CA2ALDH1A1HSD17B10THRBSMN1; SMN2 | |
| SCHEMBL186428 | 0.92 | ALDH1A1 (0.55) | ALDH1A1HSD17B10THRBSMN1; SMN2LMNA | |
| SCHEMBL1020215 | 0.92 | ALDH1A1 (0.55) | ALDH1A1HSD17B10THRBSMN1; SMN2LMNA | |
| SCHEMBL5832861 | 0.92 | ALDH1A1 (0.55) | ALDH1A1HSD17B10THRBSMN1; SMN2LMNA | |
| SCHEMBL1021740 | 0.92 | ALDH1A1 (0.55) | ALDH1A1HSD17B10THRBSMN1; SMN2LMNA | |
| SCHEMBL3289628 | 0.87 | THRB (0.47) | CA2ALDH1A1THRBLMNAKMT2A | |
| SCHEMBL145761 | 0.80 | LTA4H (0.52) | CA2CA1ALDH1A1HSD17B10HPGD | |
| SCHEMBL3321418 | 0.79 | LTA4H (0.53) | CA2ALDH1A1SMN1; SMN2LMNACYP3A4 | |
| SCHEMBL83869 | 0.79 | CA2 (0.65) | CA2CA1ALDH1A1HSD17B10HPGD | |
| SCHEMBL3291464 | 0.79 | GRIN2D (0.43) | SMN1; SMN2PTGS2CALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4263677-B1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL INT RESEARCH (NL) | 2024-10-30 | — | — | EP | claimed |
| EP-4263676-B1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL INT RESEARCH (NL) | 2024-10-30 | — | — | EP | claimed |
| US-20240025871-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL USA, INC. | 2024-01-25 | — | — | US | claimed |
| EP-4263677-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | Shell Internationale Research Maatschappij B.V. (NL) | 2023-10-25 | — | — | EP | claimed |
| EP-4263676-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | Shell Internationale Research Maatschappij B.V. (NL) | 2023-10-25 | — | — | EP | claimed |
| WO-2022133271-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL OIL COMPANY (US) | 2022-06-23 | — | — | WO | claimed |
| US-20220194914-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL OIL COMPANY | 2022-06-23 | — | — | US | claimed |
| WO-2022133243-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL OIL COMPANY (US) | 2022-06-23 | — | — | WO | claimed |
| US-20250092058-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL 118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | CANGET BIOTEKPHARMA, LLC | 2025-03-20 | — | — | US | disclosed |
| US-12187735-B2 | Matter of composition, synthesis, formulation and application of FL118 platform positions 7 and 9-derived analogues for treatment of human disease | CANGET BIOTEKPHARMA LLC (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4263677-B1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL INT RESEARCH (NL) | 2024-10-30 | — | — | EP | disclosed |
| EP-4263676-B1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL INT RESEARCH (NL) | 2024-10-30 | — | — | EP | disclosed |
| US-20240025871-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL USA, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-4263676-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | Shell Internationale Research Maatschappij B.V. (NL) | 2023-10-25 | — | — | EP | disclosed |
| US-6403633-B2 | USEFUL ANTIANGIOGENIC, ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIRESTENOTIC, ANTIINVASIVE, ANTIMETASTIC, ANTIOSTEOPOROTIC, ANTIRETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC TREATMENT AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187735-B2 | Matter of composition, synthesis, formulation and application of FL118 platform positions 7 and 9-derived analogues for treatment of human disease | TP53, BRCA1, MET | CA2 4832/4885CA1 4756/4885ALDH1A1 4214/4885 |
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | C1S, C1R, C9 | CA2 820/4885CA1 370/4885ALDH1A1 3467/4885 |
| US-20250092058-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL 118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | FLNA, FLNB, FLI1 | CA2 4874/4885CA1 4652/4885ALDH1A1 4657/4885 |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | CA2 2597/4885CA1 2080/4885ALDH1A1 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.